Indications
Therapeutic Asset Ratings
18,140 results matching 1 filter
91,565
assets
·
7,904
sponsors
·
3,128
indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Prednisone
Adult T-Cell Leukemia/Lymphoma
National Cancer Institute (NCI)
P2
B
(63)
Prednisone
Myelodysplastic Syndrome
Indiana University
P2
B
(63)
Regorafenib
Colorectal Adenocarcinoma
City of Hope Medical Center
P2
B
(63)
Romidepsin
Hodgkins Lymphoma
Memorial Sloan Kettering Cancer Center
P2
B
(63)
Romidepsin
Anaplastic Large Cell Lymphoma
Walter Hanel
P2
B
(63)
Ruxolitinib
Hodgkins Lymphoma
Seda S. Tolu
P2
B
(63)
Selumetinib
Malignant Pancreatic Neoplasm
National Cancer Institute (NCI)
P2
B
(63)
Sirolimus
Adult Acute Lymphoblastic Leukemia
Roswell Park Cancer Institute
P2
B
(63)
Sirolimus
Lymphangioleiomyomatosis
University of Cincinnati
P2
B
(63)
Solriamfetol
Hypersomnia
Duke University
P2
B
(63)
Tacrolimus
Chronic Myelomonocytic Leukemia
City of Hope Medical Center
P2
B
(63)
Tacrolimus
Fanconi Anemia
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
P2
B
(63)
Tacrolimus
Hematopoietic And Lymphoid System Neoplasm
National Cancer Institute (NCI)
P2
B
(63)
Tacrolimus
Acquired Polycythemia Vera
Thomas Jefferson University
P2
B
(63)
Tacrolimus
Primary Myelofibrosis
City of Hope Medical Center
P2
B
(63)
Thiotepa
Acute Biphenotypic Leukemia
Fred Hutchinson Cancer Center
P2
B
(63)
Thiotepa
Childhood Acute Myeloid Leukemia
Washington University School of Medicine
P2
B
(63)
Thiotepa
Diamond-Blackfan Anemia
Fred Hutchinson Cancer Center
P2
B
(63)
Tipiracil
Rectal Cancer
Academic and Community Cancer Research United
P2
B
(63)
Trifluridine
Rectal Cancer
Academic and Community Cancer Research United
P2
B
(63)
Veliparib
Breast Carcinoma
National Cancer Institute (NCI)
P2
B
(63)
Veliparib
Ovarian Carcinoma
National Cancer Institute (NCI)
P2
B
(63)
Veliparib
Primary Peritoneal Carcinoma
National Cancer Institute (NCI)
P2
B
(63)
Venetoclax
Richter Transformation
Northwestern University
P2
B
(63)
(+)-Vincristine
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
OHSU Knight Cancer Institute
P2
B
(63)
Showing 2976 to 3000 of 18,140 assets
Previous
Page 120 of 726
Next